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Abstract: Lung cancer is the leading cause of malig-
nancy-related mortality in the U.S. and is predicted to
increase over the remainder of this decade. Despite at-
tempts to advance early diagnosis and use combination
therapies, the clinical response of this cancer yields an
overall 5-year survival rate of less than 15%. Clearly, new
strategies for therapy are indicated. Although carcino-
genesis is complex, tumor growth beyond 1-2 mm3 is
dependent on angiogenesis. One of the potential mecha-
nisms that allows for tumorigenesis is dysregulation of
the balance of angiogenic and angiostatic factors that
favors net neovascularization within the primary tumor.
Numerous studies have investigated the role of a variety
of molecules in the regulation of angiogenesis. Recently,
interleukin-8 (IL-8), a member of the C-X-C chemokine
family, has been found to be an angiogenic factor. In
contrast, platelet factor 4 (PF4), another C-X-C chemok-
me, has been shown to have angiostatic properties. It is
interesting that the major structural difference between
IL-S and PF4 is the presence of the NH2-terminal ELR
(Glu-Leu-Arg) motif that precedes the first cysteine
amino acid residue of IL-S and is important in ligand/re-
ceptor interactions. We hypothesize that angiogenesis
associated with tumorigenesis is dependent on members
ofthe C-X-C chemokine family acting as either angiogenic
or angiostatic factors. This paradigm predicts that the
biological balance in the expression of these C-X-C
chemokines dictates whether the neoplasm grows and
develops metastatic potential or regresses. In this review
we discuss our recent laboratory findings that support
this contention and suggest that further elucidation of the
biology of C-X-C chemokines in the context of neovascu-
larization of nonsmall cell lung cancer will permit novel
targeted therapy aimed specifically at attenuating tumor
growth and metastasis.J. Leukoc. Biol. 57: 752-762; 1995.
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INTRODUCTION
Lung cancer is the leading cause of malignancy-related
mortality in the U.S. [1]. Although the incidence of sev-
eral other malignancies has declined or remained stable,
the occurrence of bronchogenic carcinoma has escalated
to near-epidemic proportions. Over 150,000 new cases
are diagnosed and an equal number of deaths annually
are attributable to bronchogenic carcinoma in the U.S.
[1]. Despite attempts to advance early diagnosis and use
combination therapies, the clinical response of this tumor
yields an overall 5-year survival rate for lung cancer pa-
tients of less than 15% [2]. Although lung cancer preven-
tion (i.e., cigarette smoking cessation) should remain a
high priority, a projection of lung cancer mortality
through the end of the 20th century predicts that even
with further reduction in smoking incidence, lung cancer
in this decade will increase to a rate of 53.2 deaths per
year per 100,000 population [2]. Clearly, new strategies
for therapy are necessary.
The process of tumor growth and metastasis is complex
and requires the highly orchestrated interactions of trans-
formed neoplastic cells, tissue resident cells (i.e., fi-
broblasts, macrophages, and endothelial cells), and
recruited cells (i.e., platelets, neutrophils, monocytes, and
lymphocytes) from the circulation. One of the potential
mechanisms that allows for maintenance of tumor growth
is dysregulation of the balance of angiogenic and
angiostatic factors. This dysregulation allows for the per-
petuation of tumor growth and eventual metastasis.
Based on a growing body of evidence, it is clear that a
multitude of cytokines regulate growth. However, these
cytokines may not express this full potential as individual
polypeptides but collectively in a “cytokine network.” To
study all the pathophysiological aspects of cytokine net-
works during tumor growth and metastasis is a formida-
ble task. Thus, in this review we will focus our studies on
the expression and activity of members of the C-X-C
chemokine family.
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TUMORIGENESIS IS AN EXAMPLE OF
EXAGGERATED WOUND REPAIR
For nonsmall cell lung cancer (NSCLC) growth to suc-
ceed within the host, a complex interplay must occur
between transformed neoplastic cells and nontrans-
formed resident and recruited immune and nonimmune
cells (i.e., fibroblasts, endothelial cells, and subpopula-
tions of leukocytes) [4]. Although carcinogenesis or neo-
plastic transformation is dependent on multiple genetic
and epigenetic events [5], the salient feature of all solid
tumor growth is the presence of neovascularization [6, 7].
In the absence of local capillary proliferation and delivery
of oxygen and nutrients, neoplasms cannot grow beyond
1-2 mm3 [6-8]. Folkman [7] first proposed in 1972 that
tumors are angiogenesis dependent, with tumor growth
correlating with a concomitant increase in vascular sup-
ply. In support of this contention is the finding that tu-
mor cells contiguous with neovascularization have the
highest [3H]thymidine-labeling index, whereas, tumor
cells further removed from capillaries have the lowest
[3H]thymidine-labeling index. Certain tumors have been
found to produce factors that are directly angiogenic,
whereas others may depend on neovascularization in-
duced by products of resident cells or elicited leukocytes
[ 7, 9-1 1]. These events are analogous to the formation of
granulation tissue during the evolution of wound repair
[4].
ANGIOGENESIS IS A PIVOTAL PROCESS OF
TUMORIGENESIS
Angiogenesis is one of the most pervasive and essential
biological events encountered in the mammalian organ-
ism [6, 12-14]. A number of physiological and pathologi-
cal processes, such as embryonic development, the
formation of inflammatory granulation tissue during
wound healing, and the growth of malignant solid tu-
mors, are strictly dependent on the recruitment of new
capillaries. Normally, physiological angiogenesis occurs
infrequently, yet can be rapidly induced in response to a
number of diverse physiological stimuli. Among the most
extensively studied of these angiogenesis-dependent
physiological processes is normal wound repair [15]. An
important feature of wound-associated angiogenesis is
that it is locally transient and tightly controlled. The rate
of capillary endothelial cell turnover is typically measured
in months or years [16, 17]. However, when normally
quiescent endothelial cells lining venules are stimulated,
they will degrade their basement membrane and proxi-
mal extracellular matrix, migrate directionally, divide,
and organize into new functioning capillaries invested by
a new basal lamina all within a matter of days. This dra-
matic amplification of the microvasculature is neverthe-
less temporary, for as rapidly as they are formed they
virtually disappear with similar swiftness, returning the
tissue vasculature to homeostasis. The abrupt termination
of angiogenesis that accompanies the resolution of the.
wound response suggests two possible mechanisms of
control, neither of which are mutually exclusive. First,
there is probably a marked reduction in angiogenic me-
diators. Second, a simultaneous increase occurs in the
level of angiostatic factors that inhibit new vessel growth
[8]. Although angiogenesis under conditions of normal
wound repair appears to be under strict control, during
neoplastic transformation neovascularization is exagger-
ated. It appears that tumors are continually renewing and
altering their vascular supply [7]. Interestingly, a normal
vascular mass of tissue is approximately 20%, whereas,
during tumorigenesis tumor vascular mass may be 50% of
the total tumor [7]. These findings are consistent with the
observations that angiogenic activity is both a marker of
preneoplastic-to-neoplastic transformation as well as an
event that perpetuates tumorigenesis. In addition, the
magnitude of tumor-derived angiogenesis has been di-
rectly correlated with metastasis of melanoma, prostate
cancer, breast cancer, and NSCLC [7, 18-23]. Moreover,
this would support the notion that tumor-associated
angiogenesis is dysregulated in such a manner that a bio-
logical imbalance exists that favors either the overexpres-
sion of local angiogenic factors or the suppression of
endogenous angiostatic factors [7, 18, 24]. Although most
investigations studying angiogenesis have focused on the
identification and mechanism of action of angiogenic fac-
tors, recent evidence suggests that angiostatic factors may
play an equally important role in the control of neovascu-
larization [8, 24-32].
ANGIOGENESIS IS REGULATED BY ANGIOSTATIC
FACTORS
A role for inhibitors in the control of angiogenesis was
first described with the observation that hyaline cartilage
was particularly resistant to vascular invasion [24, 25].
These studies reported that a heat labile guanidium chlo-
ride extract prepared from cartilage contained an inhibi-
tor of neovascularization. Later an identical extract from
rodent neonatal and shark cartilage was able to effectively
block neovascularization and growth of tumors in vivo
[26, 27]. Similar inhibitors of angiogenesis have been re-
ported for other cell and tissue extracts [26-30] and for a
variety of natural and artificial agents including inhibitors
of basement membrane biosynthesis [31-34], placental
RNase inhibitor [35], lymphotoxin [36], interferons
(IFNs) [37], prostaglandin synthetase inhibitors [38],
heparin binding fragments of fibronectin [39], protamine
[40], angiostatic steroids [41], several antineoplastic and
anti-inflammatory agents [42, 43], and platelet factor 4
(PF4) [44]. Many of these compounds have several bio-
logical activities. For example, PF4 blocks immunosup-
pression and inhibits bone resorption. Although most
inhibitors can act directly on the endothelial cell to block
migration and/or mitogenesis in vitro, their effects in
vivo may be considerably more complex, involving addi-
tional cells and their products.
AN IMBALANCE IN ANGIOGENIC AND ANGIOSTATIC
FACTORS MAY CONTRIBUTE TO THE PATHOLOGY
OF CHRONIC DISEASES
Several lines of evidence suggest that a biological imbal-
ance in the production of angiogenic and angiostatic fac-
tors contributes to the pathogenesis of several
angiogenesis-dependent disorders. For example, in rheu-
matoid arthritis the unrestrained proliferation of fi-
broblasts and neovascularization leads to the formation of
prolonged and persistent granulation tissue whose degra-
dative enzymes contribute to profound destruction of
joint spaces [45-47]. In contrast, monocyte-derived
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macrophage from patients with scleroderma fail to stimu-
late the expected angiogenic activity [48], suggesting that
a defect in macrophage responsiveness may contribute to
the attenuated neovascularization that is encountered in
scleroderma. Psoriasis is a well-known angiogenesis-de-
pendent disorder that is characterized by marked dermal
neovascularization. We have recently reported that kerat-
inocytes derived from psoriatic plaques are potentially
angiogenic compared with normal keratinocytes. Interest-
ingly, this aberrant phenotype is due, in part, to a com-
bined defect in the overproduction of the angiogenic
cytokine, IL-8, and a deficiency in the production of the
angiogenesis inhibitor thrombospondin-1 [49-52]. Thus,
in diseases such as rheumatoid arthritis, psoriasis, or tu-
morigenesis, neovascularization appears to be aberrantly
up-regulated. Although angiogenic and angiostatic factors
may vary among different physiological and pathological
settings, the recognition of this dual mechanism for con-
trol of angiogenesis is necessary to gain a more thorough
understanding of this complex process and its signifi-
cance in promoting tumor growth.
C-X-C CHEMOKINE FAMILY OF CYTOKINES
The fidelity of inflammation and wound repair is depend-
ent on cellular communication. Although this communi-
cation is often accomplished through direct cell-to-cell
contact via specific cellular adhesion molecules, cells may
signal one another through soluble mediators, such as
cytokines. These polypeptide molecules often have pleiot-
ropic effects on a number of biological functions includ-
ing proliferation, differentiation, recognition, and cellular
recruitment. Their actions are mediated through parac-
rine and autocrine signaling and under certain conditions
they can behave as hormones. Recently, a new family of
cytokines have been identified that appear to have prom-
flammatory and reparative activities [53-57]. These cytok-
ines in their monomeric forms are all less than 10 kDa
and are characteristically basic heparin binding proteins.
This family displays four highly conserved cystemne amino
acid residues, with the first two cystemnes separated by one
nonconserved amino acid residue. In general, these cytok-
ines appear to have specific chemotactic activity for neu-
trophils. Because of their chemotactic properties and the
presence of the C-X-C cysteine motif, these cytokines have
been designated the C-X-C chemokine family. Interest-
ingly, these chemokines are all clustered on human chro-
mosome 4 and exhibit between 20% to 50% homology on
the amino acid level [53-57]. Over the last decade, 12
different C-X-C chemokines have been identified and in-
dude PF4, NH2-terminal truncated forms of platelet basic
protein (PBP; connective tissue-activating protein-Ill
[CTAP-III], -thromboglobulin [TG], and
tivating protein-2 [NAP-2]), interleukin-8 (IL-8), growth-
related oncogene (GROa), GRO3, GROy, IFN-y-inducible
protein (IP-lO), monokine induced by IFN-y (MIG), epi-
thelial neutrophil-activating protein-78 (ENA-78), and
granulocyte chemotactic protein-2 (GCP-2) [53-60]. The
NH2-terminal truncated forms of PBP are generated
when PBP is released from platelet a-granules and under-
goes proteolytic cleavage by monocyte-derived proteases.
PF4, the first member of the C-X-C chemokine family to
be described, was originally identified for its ability to
bind to heparin, leading to the inactivation of heparin’s
anticoagulation function [61]. Both IP-lO and MIG are
IFN-inducible C-X-C chemokines [58, 62]. Although IP-lO
appears to be induced by all three interferons (IFN-a,
IFN-, and IFN-y), MIG is unique in that it appears to be
only expressed in the presence of IFN-y [58]. Although
IFN-y induces the production of IP-lO and MIG, this cy-
tokine has been found to attenuate the expression of both
IL-8 and ENA-78 (63; and unpublished observations).
These findings would suggest that members of the C-X-C
chemokine family demonstrate disparate regulation in
the presence of IFN-y. GROa, GRO, and GRO’y and are
closely related C-X-C chemokines, with GROa originally
described for its melanoma growth stimulatory activity
[64-66]. IL-8, ENA-78, and GCP-2 were all initially identi-
fled on the basis of their ability to induce neutrophil
activation and chemotaxis [53-60]. IL-8 has been found
to be produced by an array of cells including monocytes,
alveolar macrophages, neutrophils, keratinocytes, me-
sangial cells, epithelial cells, hepatocytes, fibroblasts, and
endothelial cells [53-57, 67-80]. Interestingly, IL-8 is ex-
pressed in neoplasms and produced by a number of trans-
formed neoplastic cells [72, 75, 81-83]. Although
numerous investigations have shown both in vivo and in
vitro the importance of IL-8 in acute inflammation, as a
chemotactic/activating factor for neutrophils, only re-
cently has it become apparent that this C-X-C chemokine
may be important in angiogenesis associated with tu-
morigenesis.
ROLE OF C-X-C CHEMOKINES IN ANGIOGENESIS
Our laboratory and others have found that IL-8 is a po-
tent angiogenic factor [47, 84, 85]. Recombinant IL-8 me-
diates both endothelial cell chemotactic and proliferative
activity in vitro and angiogenic activity in vivo. We found
that IL-8 induced similar angiogenic activity as basic fibro-
blast growth factor (bFGF) [47]. Because monocytes/
macrophages may represent a major source of angiogenic
activity in wounds, other chronic diseases, and solid tu-
mors [13], we extended our studies to determine whether
IL-8 was a predominant angiogenic factor liberated by
activated human monocytes or by synovial macrophages
isolated from rheumatoid arthritis synovial tissues [47].
Conditioned medium from both populations of mononu-
clear phagocytes induced significant angiogenic activity
that was attributable to IL-8 [47]. To further demonstrate
that the angiogenic effect was attributable to IL-8, we
used an IL-8 antisense oligonucleotide strategy to inhibit
the production of IL-8 at the pretranslational level [47].
The conditioned medium from monocytes treated in the
presence of IL-8 antisense inhibited endothelial chemo-
tactic activity by 84% compared with the IL-8 sense oh-
gonucleotide-treated monocytes. Similar results were
found in the in vivo corneal micropocket model of angio-
genesis. These findings indicated that IL-8, at concentra-
tions of approximately 1 nM, functioned as a mediator of
angiogenesis. This amount of IL-S compares with
amounts reported for the induction of corneal angiogenic
activity by tumor necrosis factor-a, aFGF, bFGF, angio-
genin, angiotropin, and endothelial cell growth factor
[47].
Another member of the C-X-C chemokine family, PF4,
has been shown to have angiostatic properties in nanomo-
lar to micromolar concentrations [44] and to attenuate
the growth of tumors in vivo [56]. Interestingly, these
studies had initially demonstrated that the angiostatic ac-
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tivity of PF4 was due to its heparin binding domain
(within the COOH-terminal of the molecule) [44, 86].
However, recent studies have now shown that a PF4 mu-
tant that lacks the heparin binding domain, and func-
tional heparin binding is equipotent in vivo to native PF4
for the attenuation of tumor growth [87]. The above find-
ings would suggest that members of the C-X-C chemokine
family function as either angiogenic or angiostatic factors
in regulating neovascularization, and the biological bal-
ance in the magnitude of expression of these angiogenic
and angiostatic C-X-C chemokines within a tumor could
dictate overall tumor-derived angiogenic activity. Al-
though it remains unclear whether the COOH-terminal of
these chemokines dictates their biological role in angio-
genesis, the differences in C-X-C chemokine function
could also be explained by other structural domains. Re-
cently, both H#{233}bert et a!. [88] and Clark-Lewis et al. [89]
have demonstrated a salient amino acid sequence in the
primary structure of the C-X-C chemokine family that
appears, in part, to account for the ability of these
chemokines to function in neutrophil chemotaxis and
activation. They demonstrated that the three amino acid
residues that immediately preceded the first cysteine
amino acid are critically important in the binding and
activation of neutrophils. These amino acids are Glu-Leu-
Arg, the ELR motif, which is absent in certain members
of the C-X-C chemokine family (PF4, IP-lO, and MIG) that
display markedly reduced potency in mediating neutro-
phil chemotaxis. Interestingly, when the ELR motif was
introduced into PF4, this chemokine gained 1000-fold
potency in mediating neutrophil chemotaxis [89]. Thus,
these structural differences, in part, may explain the dis-
parity of angiogenic activity of the C-X-C chemokine fam-
ihy and support the hypothesis that a biological imbalance
in the expression of angiogenic and angiostatic C-X-C
chemokines may lead to the perpetuation of neovasculari-
zation during tumor growth and metastasis.
ROLE OF IL-8 AS AN ANGIOGENIC FACTOR IN
NSCLC
Previous studies have demonstrated that human tumors
and neoplastic cell lines may directly elaborate IL-8 [72,
75, 51-83, 90-92]. Because angiogenesis is critical to tu-
morigenesis and metastasis, we extended our initial dis-
covery of IL-S as an angiogenic factor to assess whether
this C-X-C chemokine was present in NSCLC and whether
it contributed to overall tumor-derived angiogenic activity
[93]. We found significantly elevated IL-8 levels in natural
human NSCLC, by using a specific ELISA, that were four-
fold greater than normal lung tissue [93]. Results from
IL-S immunohistochemistry of tumor sections confirmed
a heterogeneous pattern of tumor cell production of IL-8
from both adenocarcinomas and squamous cell carcino-
mas of the lung [93]. The heterogeneity of the tumor cell
expression was of interest, especially because we had pre-
viously shown that only 36% to 38% of adenocarcinoma
cells (A549 cell line) expressed IL-8 [75]. The findings of
heterogeneous expression of IL-8 by tumor cells suggests
that specific subclones of neoplastic cells may exist and
function as the primary cellular source of tumor-derived
IL-S. Our results also revealed that nontransformed stro-
ma! cells within the host desmoplastic response to the
tumor were also serving as significant cellular sources for
IL-S, especially in response to the squamous cell carci-
noma [93]. Importantly, these specific findings may re-
flect the different clinical behavior of squamous cell and
adenocarcinomas. The more aggressive course of adeno-
carcinomas could be related to their capacity to generate
a sufficient angiogenic signal [IL-8], independent from
the surrounding host-responding immune and nonim-
mune cells. The observation of a minimal inflammatory
cell infiltrate in the tumor specimens, despite the pres-
ence of IL-8, was unexpected and supported the conten-
tion that IL-S may have other biological functions in the
context of NSCLC.
Because it was apparent that NSCLC was associated
with significantly elevated levels of IL-S, we next deter-
mined whether IL-S contributed to overall tumor-derived
angiogenic activity. By using neutralizing antibodies to
IL-8, we found that IL-S accounted for 42% to 80% of the
angiogenic activity for each of the tumor specimens, as
determined by bioassays of angiogenesis [93]. The above
data suggested that a significant portion of tumor-derived
angiogenic activity was mediated directly by IL-S. Al-
though IL-8-dependent angiogenic activity represented a
significant proportion of overall NSCLC-derived angio-
genesis, we wanted to compare the relative contribution
of IL-S to other known angiogenic factors in NSCLC.
Neutralizing antibodies to IL-S resulted in a significant
reduction of endothehial cell chemotactic activity in re-
sponse to NSCLC tissue, with a decline to 75%, 39%, and
61% of the standard bioactivity, respectively, for adeno-
carcinoma, squamous cell carcinoma, and A549 (adeno-
carcinoma) samples. In contrast, anti-bFGF antibodies
had no significant effect on the endothehial cell chemo-
taxis in response to samples of A549 cells/tissue or
squamous cell carcinoma tissue; however, neutralizing
anti-bFGF antibodies reduced the endothelial cell chemo-
tactic activity from adenocarcinoma tissue by 35% of the
standard bioactivity. Interestingly, the neutralization of
transforming growth factor-a had no significant effect on
the chemotaxis in response to adenocarcinoma or to the
A549 cell/tissue; however, these antibodies resulted in a
significant reduction (45%) in the endothelial cell chemo-
tactic response to squamous cell carcinoma tissue. Al-
though bFGF and transforming growth factor-a have
been previously described as potential angiogenic factors
involved in tumor angiogenesis [4, 7, 92, 94, 95], these
studies were the first to demonstrate that a primary angio-
genic signal for NSCLC neovascularization was directly
mediated by tumor-associated IL-S.
ROLE OF C-X-C CHEMOKINES IN MEDIATING
ANGIOGENESIS IN THE CONTEXT OF
TUMORIGENESIS: OUR HYPOTHETICAL MODEL
The experiments designed in our laboratories have fo-
cused on the role of angiogenic and angiostatic C-X-C
chemokines and whether a biological imbalance in their
expression favors tumor-derived angiogenic activity. We
hypothesize that angiogenesis associated with NSCLC tu-
mor growth is dependent on members of the C-X-C
chemokine family acting as either angiogenic or
angiostatic factors (Fig. 1). This paradigm predicts that a
shift in the balance of expression of these C-X-C chemok-
ines dictates whether the neoplasm grows and develops
metastatic potential or regresses. The net angiogenic ac-
tivity during the progression of tumorigenesis is mediated












Fig. 1. The role of C-X-C chemokines in mediating angiogenesis in the
context of tumor genesis: our hypothetical model. ELR, chemokines
containing the ELR motif; XXX, chemokines that lack the ELR motif.
angiogenic C-X-C chemokines (ELR-C-X-C) compared
with the angiostatic C-X-C chemokines (XXX-C-X-C).
However, the magnitude of expression and the biological
imbalance will favor the production of angiogenic C-X-C
chemokines (ELR-C-X-C). This effect results in tumor
growth, invasion, and metastasis beyond the confines of
its primary site of origin. In contrast, the generation of
IP-lO and MIG will have a negative effect on tumorigene-
sis through a reduction in tumor-derived angiogenic activ-
ity. These C-X-C chemokines are primarily induced by
IFN-y, which is known to be attenuated by IL-b. The
production of IL-lO by both neoplastic cells and sur-
rounding nontransformed immune and nonimmune cells
will have a significant, yet indirect, impact on the genera-
tion of angiostatic (XXX-C-X-C) chemokines (IP-lO and
MIG). Under these circumstances, IL-lO expression in the
context of tumorigenesis can be viewed as an indirect
promoter of angiogenesis via the down-regulation of IFN-
.y. The experimental model of human NSCLC/SCID
mouse chimera has provided the opportunity to test
whether either attenuation of angiogenic (ELR-C-X-C)
chemokines or accentuation of angiostatic (XXX-C-X-C)
chemokines promotes tumor regression.
PRELIMINARY STUDIES
The major aims of our experiments were to study the role
of C-X-C chemokines as they relate mechanistically to the
pathophysiological consequences of tumorigenesis. The
following preliminary data demonstrates that specific
members of the C-X-C chemokine family of chemotactic
cytokines are either angiogenic or angiostatic mediators
of neovascularization. In addition, these data support the
notion that these C-X-C chemokines are likely candidates
to target novel future specific therapies.
C-X-C CHEMOKINES (ELR MOTIF) INDUCE AND
IP-lO AND PF4 (NON-ELR MOTIF) ATTENUATE
ANGIOGENESIS
We postulated that the members of the C-X-C chemokine
family may exert disparate effects in mediating angio-
genesis for primarily four reasons. First, members of the
C-X-C chemokine family that display binding and activa-
tion of neutrophils share the same ELR motif homology
that immediately precedes the first cysteine amino acid
residue, whereas, PF4, IP-lO, and MIG lack this motif [88,
89]. Second, IL-S (contains ELR motif) is angiogenic and
PF4 (lacks the ELR motif) is angiostatic. Third, the IFNs
(IFN-a, IFN-, and IFN-?) are all known inhibitors of
wound repair, especially angiogenesis and reepithehiahiza-
tion [37, 92, 95-1 10], however, these cytokines up-regu-
late IP-lO and MIG from a nuniber of cells, including
keratinocytes, fibroblasts, endothelial cells, and mononu-
clear phagocytes [58, 62]. We hypothesize that IFNs may
be exerting their negative influence in wound repair by
up-regulating the production of IP-lO and MIG, which
may act in an autocrine and paracrine manner to sup-
press angiogenesis. Finally, we and others have found that
IFN-a, IFN-, and IFN-y are potent inhibitors of both
monocyte-derived IL-8 and ENA-78 (63; and unpublished
observations), supporting the notion that IFN-a, IFN-,
and IFN-y may shift the biological balance of C-X-C
chemokines toward a preponderance of angiostatic C-X-C
chemokines. To test this postulate, we performed endo-
thelial cell chemotaxis in the presence or absence of C-X-
C chemokines that contain the ELR motif (IL-8, ENA-78,
GCP-2, GROa, GROf, GROy, PBP, CTAP-III, and
and C-X-C chemokines lacking the ELR motif (IP-lO and
PF4). In a similar fashion to IL-S, all of the C-X-C chemok-
ines that contained the ELR motif demonstrated signifi-
cant endothehial cell chemotactic activity, whereas the
endothehial cell chemotactic activity induced by either IP-
10 or PF4 were similar to control (background). In addi-
tion, ENA-78, GCP-2, GROa, GRO, GROy, and NAP-2
in a similar concentration to IL-S demonstrated signifi-
cant cornea! neovascularization without any evidence for
inflammatory cellular infiltration.
To delineate whether IP-lO (C-X-C chemokine lacking
the ELR motif) could modulate C-X-C chemokine (ELR
motif present)-induced endothehial cell chemotactic activ-
ity, IL-8, GROa, CTAP-III, and NAP-2 were assessed for
endothelial cell chemotaxis in the presence of IP-lO. The
presence of IP-lO significantly attenuated endothelial cell
chemotactic activity in response to C-X-C chemokines
containing the ELR motif. In addition, PF4 in a similar
fashion to IP-lO also attenuated C-X-C chemokine (ELR
motif present)-induced endothelial cell chemotactic activ-
ity. Furthermore, by using the corneal micropocket
model of neovascularization, IP-lO in equivalent molar
concentrations was found to attenuate IL-S-, ENA-7S-,
GCP-2-, and GROa-induced angiogenesis. These findings
support the premise that members of the C-X-C chemok-
me family may be acting as either angiogenic or
TABLE 1. C-X-C Chemokines Display Disparate Angiogenic Activity















angiostatic factors (Table 1). The net biological balance
of these C-X-C chemokines, in the context of tumorigene-
sis, may play an important role in modulating NSCLC
neovascularization.
PRESENCE OF C-X-C CHEMOKINES IN NSCLC
The evidence that C-X-C chemokines could function as
either angiogenic or angiostatic factors, depending on the
presence of the ELR motif, lead to our investigation as to
whether C-X-C chemokines were present in natural hu-
man NSCLC and whether they contributed to overall
NSCLC tumor-derived angiogenic activity. IL-S, ENA-78,
and GROa were found in a 4-, 3-, and 2.5-fold excess,
respectively, in tumor tissue compared with normal lung
tissue normalized to total protein (TP). Normal lung tis-
sue contained 2.6 ± 0.7, 15 ± 6, and 6 ± 2.5 ng/mg TP of
IL-S, ENA-7S, and GROa compared with 11.9 ± 3.5,
43.6 ± 10, and 1 1.5 ± 2.5 ng/mg TP for tumor specimens,
respectively. There were similar elevations of IL-S and
ENA-78 from both adenocarcinomas and squamous cell
carcinomas, whereas GROa was found to be especially
elevated in squamous cell (17.6 ± 7.5 ng/mg TP) carcino-
mas. In contrast, PF4 levels were found in the carcinoma
tissue homogenates to be equivalent to normal lung tissue
(592.4 ± 127.8 ng/mg TP and 579.1 ± 195.3 ng/mg TP
for tumors and normal lung tissue, respectively). Al-
though IP-lO levels trended toward being greater in tu-
mors than in normal lung tissue homogenates, IP-lO was
significantly lower in adenocarcinomas (0.9 ± 0.5 ng/mg
TP) than in normal lung tissue (3.6 ± 2 ng/mg TP). Im-
portanthy, these specific findings may be reflected in the
different clinical behaviors of squamous cell carcinoma
and adenocarcinoma NSCLCs. The more aggressive
course of adenocarcinomas could be related to their ca-
pacity to generate a greater angiogenic compared with
angiostatic C-X-C chemokine signal. To further substanti-
ate that IP-lO may be acting as an endogenous angiostatic
C-X-C chemokine to balance the effect of angiogenic fac-
tors in the context of NSCLC, we assessed squamous cell
carcinoma tissue homogenates for angiogenesis in the
presence of neutralizing IP-lO or control antibodies. By
using either endothehial cell chemotaxis or a cornea! mi-
cropocket model of neovascularization, we found that
neutralizing IP-lO antibodies (without evidence of
lipopolysaccharide contamination) significantly aug-
mented tumor-derived angiogenic activity by twofold.
These findings support the presence of an imbalance in
ELR-C-X-C compared with XXX-C-X-C chemokines, with
the balance favoring a greater presence of angiogenic
C-X-C chemokines in NSCLC tumors.
HUMAN NSCLC/SEVERE COMBINED
IMMUNODEFICIENT (SCID) MOUSE CHIMERA AS A
MODEL FOR HUMAN TUMORIGENESIS
Although neoplastic transformation is dependent on mul-
tiple genetic and epigenetic events [5], the success of
tumorigenesis is dependent on the complex biological
interplay between the neoplastic cells and the resident
and recruited host-responding cells. For example, in the
absence of local neovascularization these neoplasms
could not grow beyond 1-2 mm3 [6-8]. Thus, to effec-
lively study the complex biology of human solid tumors,
the use of human tumor xenografts in immunodeficient
mice have provided significant insight into the biology of
tumor growth and metastasis [1 1 1-120]. Our preliminary
data supports the notion that specific members of the
C-X-C chemokine family are important cytokines involved
in orchestrating a significant portion of the angiogenic
response during tumorigenesis and that other members
may be important in attenuating this response. To char-
acterize the qualitative and quantitative presence of these
angiogenic and angiostatic C-X-C chemokines, as well as
determine their net contribution to human NSCLC tu-
morigenesis in vivo, we have transplanted either intact
natural human NSCLC or NSCLC cell lines (A549, ade-
nocarcinoma and Calu-1, squamous cell carcinoma) into
SCID mice to create a human NSCLC/SCID mouse chi-
mera. The mice were evaluated before xenograft to have
a murine serum Ig concentration of <1 .tg/ml by ELISA.
Freshly isolated intact NSCLC (adenocarcinoma) were cut
into 1 mm5 and placed subcutaneously into the bilateral
flanks of SCID mice and allowed to grow for 4 weeks. At
this time point the tumors measured 4-9 mm in diameter
and the mice were killed. Immunohistochemistry for IL-S
and ENA-78 demonstrated the immunolocahization of
these C-X-C chemokines within the viable NSCLC cells,
stromal cells, and mononuclear cells, whereas the control
antibodies failed to show nonspecific staining. These find-
ings suggested that natural human NSCLC remained vi-
able in SCID mice and that they continue to express both
IL-S and ENA-7S that may have allowed them to generate
angiogenic activity and survive in the SCID mouse host.
Because our central hypothesis is that overall tumor-de-
rived angiogenesis is dependent on an imbalance in the
production of members of the C-X-C chemokine family
that act as angiogenic rather than angiostatic factors, we
next assessed in vitro whether human NSCLC cell lines
(A549 and Calu-1) produced disparate levels of angio-
genic (IL-8, ENA-78, and GROa) and angiostatic (PF4 and
IP-lO) C-X-C chemokines. Both A549 and Calu-1 human
NSCLC cell lines were found to constitutively produce
high levels of angiogenic C-X-C chemokines. Interest-
ingly, the A549 cells were found to constitutively produce
greater levels of angiogenic C-X-C chemokines, and when
grown in SCID for 4 weeks, were found to induce tumors
twofold greater in size than the Calu-1 NSCLC cell line.
These findings corroborate the previous findings that
A549 cells display greater tumorgenicity and spontaneous
metastasis than Calu-1 cells in vivo [119-121]. Although
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these in vitro studies were important to establish whether
an imbalance in the production of angiogenic compared
with angiostatic C-X-C chemokines existed in NSCLC cell
lines, we next assessed whether an imbalance in their
production occurred in vivo during tumorigenesis of
A549 NSCLC cells in a SCID mouse host.
SCID mice received 106 A549 cells suspended in 100 jtl
of phosphate-buffered saline to each flank. The mice were
killed in a time-dependent manner at 2, 3, 4, 5, 6, and 7
weeks postxenograft and tumors were analyzed for tumor
growth, and tumor-derived and plasma levels of C-X-C
chemokines standardized to either TP or volume (biopsy).
Immunolocalization of IL-S from A549 tumors at week 7
demonstrated a heterogeneous expression pattern with
35 ± 6% of the cells expressing IL-S protein by image
analysis, whereas IL-S expression from spontaneous A549
tumor metastasis to the lungs of SCID mice at 7-S weeks
demonstrated a more homogenous pattern of immunolo-
cahization of IL-S, with more than 80% of the cells express-
ing IL-8 protein by image analysis. Moreover, when A549
tumors in SCID mice and plasma from these mice were
analyzed for the presence of C-X-C chemokines, we found
a significant correlation of the temporal expression of
angiogenic compared with angiostatic C-X-C chemokines
during tumorigenesis. These studies substantiated that
the production of angiogenic C-X-C chemokines paral-
leled tumor growth and supported our contention that an
imbalance in angiogenic and angiostatic C-X-C chemoki-
nes exist during tumorigenesis. However, these studies
did not demonstrate whether these angiogenic C-X-C
chemokines directly contributed to an imbalance favoring
net angiogenesis leading to tumor growth or tumor sur-
‘ival. To assess whether IL-S directly contributed to tu-
mor growth and survival, human NSCLC (A549)
tumorigenesis was allowed to occur in SCID for a period
of 4 weeks before the initiation of in vivo passive immu-
nization with neutralizing antibodies to IL-8 (every other
day during weeks 5, 6, and 7 of tumor growth). We found
the tumors (at 8 weeks) to demonstrate markedly more
central necrosis in animals that had received neutralizing
antibodies to IL-8 compared with animals receiving con-
trol antibodies. In addition, morphological analysis, thre-
sholded to NSCLC cell nuclear size, showed a significant
reduction in cellularity of the tumors that were exposed
to neutralizing IL-S antibodies. The above findings pro-
vide evidence that supports our contention that the ELR
motif containing C-X-C chemokines are important angio-
genic molecules during tumorigenesis, and that an imbal-
ance in their expression compared with angiostatic C-X-C
chemokines, dictates their role in mediating net tumor-
derived angiogenesis during tumorigenesis. Furthermore,
the use of the human NSCLC/SCID mouse model has
allowed us to validate our central hypothesis and examine
the biology of C-X-C chemokines as they relate to angio-
genesis in vivo. This model of human tumorigenesis has
allowed the unique opportunity to examine the temporal
magnitude, cellular sources, and contribution of the
angiogenic and angiostatic C-X-C chemokines to the evo-
lution of tumorigenesis and spontaneous metastasis.
CYTOKINE NETWORKS THAT MAY PROMOTE
ANGIOGENIC C-X-C CHEMOKINES
The above preliminary data coupled with what is known
regarding the role of IFNs in wound repair, suggest that
the magnitude of IFN expression would be a pivotal event
in locally regulating both angiogenic (through negative
feedback) and angiostatic (through positive feedback) C-
X-C chemokine production. IFNs are pleiotropic cytoki-
nes that exert a broad range of immunomodulatory and
inflammatory effects, however, they share a salient fea-
ture of cellular growth inhibition. IFN-a and 1FN43 are
produced primarily by mononuclear phagocytes and fi-
broblasts, respectively, whereas IFN-y is produced by
CD4 and CD8 T cells and natural killer cells [109, 110].
These IFNs are all known inhibitors of wound repair,
specifically they appear to have a significant inhibitory
influence on endothelial cell biology [37, 90, 95,
102-1 10]. This supports the notion that IFNs can modu-
late suppression of neovascularization through both di-
rect and indirect pathways. Although IFN-a, IFN-, and
IFN-y can inhibit the cellular expression of angiogenic
C-X-C chemokines, these IFNs are important for the in-
duction of angiostatic C-X-C chemokines (IP-lO and
MIG). The net effect of IFN stimulation would be to shift
the biological balance in favor of angiostatic C-X-C
chemokines. This potential mechanism could be opera-
tive during the later stages of normal wound repair,
where new capillary blood vessel formation is rapid, un-
der strict control, and undergoes marked regression to a
physiological steady-state level. In contrast, angiogenesis
during neoplastic transformation is exaggerated [7, 8].
This perpetual neovascularization during tumorigenesis
suggests two possible pathological mechanisms, neither of
which are mutually exclusive: ( 1 ) tumorigenesis is associ-
ated with an increase in the synthesis and/or elaboration
of angiogenic mediators and (2) tumorigenesis is associ-
ated with reduced levels of substances that inhibit neovas-
cularization. Because our preliminary data supported the
former, we also postulated that these neoplasms may be
associated with equivalent or reduced levels of IFN-y corn-
pared with normal lung tissue, which would support the
latter. To test this hypothesis, we analyzed human tissue
homogenates of both normal and NSCLC for the pres-
ence of IFN-y by using an IFN-y specific ELISA. IFN-y
concentrations from tumor samples were found to be
similar to normal hung tissue. These findings corrobo-
rated the study by Vitolo et a!. [122] who found that
cytokine expression of mRNA (TH-1 profile) from tumor-
infiltrating lymphocytes was unexpectedly reduced within
solid tumors compared with other chronic inflammatory
disorders. The above findings may reflect the reduced
immunogenicity of tumor-associated antigens, however,
an alternative explanation may be the ability of the tumor
or host-responding cells to produce immunosuppressive
factors that may directly impact on the local production
of IFN-y.
IL-b is a recently characterized cytokine that demon-
strates varied immunosuppressive bioactivity. Since its in-
itial isolation by Mosmann et a!. [123-126] in 1988,
investigations have elucidated many of the immunological
properties of this cytokine. Originally identified as a prod-
uct of CD4 T cells, IL-b is also produced by monocytes,
macrophages, B cells, certain populations of CDS T cells,
and Epstein-Barr virus-transformed lymphobhastoid cells
lines [123, 124, 126-130]. Recent work has demonstrated
that epidermal cells may also elaborate IL-lO [131]. Func-
tional studies reveal that IL-b has profound effects on
monocytes, resulting in alterations in cell morphology
and cytotoxicity, down-regulation of the expression of
major histocompatibility complex class II antigens, and
inhibition of proinflammatory cytokine production
[132-137]. Furthermore, IL-b also exerts direct effects
on the growth and function of T cells, B cells, and mast
cells [123, 124]. These specific actions result in the capac-
ity for IL-b to attenuate a wide range ofeffector immune
responses, including T cell cytokine (i.e., IFN-’y) produc.
tion and antigen-specific proliferation, B cell Ig synthesis,
and the elaboration of tumor necrosis factor-a and IFN-y
by natural killer cells [123, 124]. IL-b may play an impor-
tant role in homeostasis under normal circumstances;
however, IL-b, in the context of tumorigenesis, may be a
major immunosuppressive factor that attenuates the local
generation of IFN-y. To test this premise, we investigated
the capacity of NSCLC to produce IL-b [138]. We found
increased levels of antigenic IL-b in tissue homogenates
of NSCLC ( 13.7 ± 2.5 ng/mg TP) compared with normal
lung tissue (5.8 ± 0.8 ng/mg TP). No significant differ-
ence in IL-b levels were seen between the squamous cell
carcinoma ( 15.4 ± 3.7 ng/mg TP) and adenocarcinoma
(12.3 ± 4.2 ng/mg TP). To determine the cellular source
of IL-b in the NSCLCs, immunohistochemical staining
of NSCLC showed primary localization of antigenic IL-lO
to individual NSCLC cells [135]. In addition, immunolo-
calization using HAM56, (Enzo Diagnostics, Inc., Farm-
ingdale, NY), a murine monoclonal antibody against
human mononuclear cells, confirmed that tumor cells,
rather than immune cells, were the primary cellular
source of antigenic IL-lO [138]. Because IL-b had pre-
viously been demonstrated to be produced by epidermal
cells [131], we analyzed the conditioned medium of sev-
era! unstimulated human NSCLC cell lines (A549, A427,
and Calu-6) for the constitutive production of IL-b.
These cells produced 6.3 ± 1 ng/ml, 1.9 ± 0.9 ng/ml, and
7.6 ± 1 . 1 ng/ml of IL-i 0 after 24 h of culture, respectively
[135]. These findings demonstrate that NSCLC cell lines
can elaborate IL-b. Thus, IL-lO may play an important
role in impairing immune cell effector function and en-
able the NSCLC to evade host immune defenses; how-
ever, IL-b suppression of IFN-y may play an equally
important role in perpetuating tumor-associated neovas-
cularization.
Our data demonstrates and supports the potential pres-
ence of an imbalance in the expression of angiogenic and
angiostatic C-X-C chemokines during tumorigenesis that
favors the tumor-derived angiogenesis. In addition, the
presence of augmented levels of IL-lO in NSCLC may
favor the notion that IL-b may promote angiogenesis via
a direct role in attenuating IFN-y and therefore, indirectly
inhibiting angiostatic C-X-C chemokines during tu-
morigenesis. The further elucidation of the biology of
these cytokines will provide new insight into the specific
aspects of C-X-C chemokine biology responsible for
NSCLC angiogenesis and subsequent tumorigenesis and
metastasis.
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